Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Medwave ; 24(1): 2762, 29-02-2024.
Article in English, Spanish | LILACS-Express | LILACS | ID: biblio-1532751

ABSTRACT

Introducción Más de 600 mil personas en Chile viven con obesidad mórbida. La incorporación de intervenciones terapéuticas eficaces, seguras y costo-efectivas es crítica para los sistemas de salud y esquemas de aseguramiento. En el año 2022 se incorporaron al arancel de modalidad de libre elección del Fondo Nacional de Salud dos códigos de pago asociado a diagnóstico para cirugía bariátrica: gástrico y manga gástrica. El objetivo fue caracterizar la ejecución del programa de mecanismo de pago tipo pago asociado a diagnóstico de cirugía bariátrica en su primer año de implementación. Métodos Estudio descriptivo y observacional de abordaje pragmático de la ejecución nacional del pago asociado a diagnóstico en cirugía bariátrica. Se examinaron variables de caracterización sociodemográfica (sexo, tramos etarios y tramos del Fondo nacional de Salud) y caracterización de cirugías según código desagregadas por prestador público o privado, periodo de emisión, gasto unitario, copago, y préstamos médicos, entre marzo y diciembre de 2022. Resultados Se registraron n = 13 118 cirugías (45,81% versus 54,19% manga), de las cuales n = 2424 (18,48%) emplearon préstamos médicos. Un 85,01% (p = 0,01) de los procedimientos fueron en mujeres; en personas entre 35 y 39 años (20,15%); y 45,12% en beneficiarios del tramo B. El 99,21% de las cirugías se realizó en prestadores privados. Diez de estos concentraron el 50% de la actividad (rango n = 1200 a 426 cirugías anuales; n = 4,8 a 1,7 cirugías por día hábil). El gasto total del programa fue $71 626 948 350 CLP, explicando un 5,04% de la actividad total del Programa nacional de Pago Asociado a Diagnóstico. Conclusiones La implementación de este bono para cirugía bariátrica benefició a más de 13 mil personas que viven con obesidad, mayormente mujeres, en edades productivas, y con capacidad de compra. Como estrategia de equidad, independientemente de la vía de acceso mediante el bono, será importante cautelar la actividad en la red pública.


Introduction More than 600 thousand people in Chile live with morbid obesity. Effective, safe, cost-effective therapeutic interventions are critical for healthcare systems and insurance schemes. In 2022, two bundled payment codes for bariatric surgery (gastric bypass and gastric sleeve) were incorporated into the National Health Fund's free-choice modality fee scheme. The objective was to characterize the execution of this payment mechanism program associated with bariatric surgery diagnosis in its first year of implementation.More than six hundred thousand people in Chile are estimated to live with morbid obesity. Effective, safe, cost-effective therapeutic interventions are critical for health systems and insurance schemes. In 2022, FONASA incorporated two Bariatric Surgery codes into the Free Choice Modality: Gastric Bypass and Sleeve Gastrectomy. Our objective was to characterize the execution of the Bariatric Surgery Bundled Payment Program in its first year of implementation. Methods Descriptive and observational study of the pragmatic approach of the national execution of the payment associated with diagnosis in bariatric surgery. We examined sociodemographic variables (sex, age brackets, and National Health Fund tranches) and characterization of surgeries by code broken down by public or private provider, period of issue, unit cost, co-payment, and medical loans between March and December 2022. Results We recorded n = 13 118 surgeries (45.81% bypass versus 54.19% sleeve), of which n = 2424 (18.48%) used medical loans. A total of 85.01% (p = 0.01) of the procedures were in women, in people between 35 and 39 years of age (20.15%), and 45.12% in beneficiaries of tranche B. Private providers performed a total of 99.21% of the surgeries. Ten accounted for 50% of the activity (range n = 1200 to 426 surgeries per year; n = 4.8 to 1.7 surgeries per working day). Total program expenditure was $71 626 948 350 CLP, accounting for 5.04% of the total activity of the national Diagnosis Associated Payment Program. Conclusions The implementation of this bariatric surgery voucher benefited more than 13 thousand people living with obesity, mostly women of productive ages and with purchasing capacity. As an equity strategy, regardless of the access route through the voucher, it will be important to safeguard the activity in the public network.

2.
Hematol., Transfus. Cell Ther. (Impr.) ; 43(1): 50-57, Jan.-Mar. 2021. tab, graf
Article in English | LILACS | ID: biblio-1154292

ABSTRACT

ABSTRACT Introduction: Chronic Myeloid Leukemia (CML) is a myeloproliferative disease that affects mainly adults between 50 and 55 years. In Brazil, information from the Sistema Único de Saúde (SUS) Outpatient Information System indicates that 12,531 patients had the Autorização de Procedimento Ambulatorial (APAC) approved for the CML treatment in 2017. Disease monitoring through molecular response evaluation is critical to the care of CML patients. The quantitative PCR test (real-time polymerase chain reaction) provides adequate evaluation parameters that allow the health professional to intervene at the right moments in order to reduce the chance of progression of the disease, providing the best outcome to the patient, including the possibility of treatment discontinuation for eligible patients. Although the test is included in the Clinical Protocol and Therapeutic Guidelines (PCDT) of CML, it is not possible to monitor the molecular response within SUS since there is no reimbursement for this test. Objective: Obtain expert recommendations on the importance, financing, and reimbursement of molecular monitoring in SUS. Methods: Six CML experts with different perspectives participated in the panel. The discussion was based in the main publications about the quantitative PCR test in CML monitoring. Results: Experts' recommendations: Molecular monitoring should be part of the integral treatment of patients with CML to reduce the chances of disease progression and costs to the health system; The government should put into practice what is provided in the PCDT of Chronic Myeloid Leukemia in Brazil: performing the monitoring of the molecular response via quantitative PCR; The government should create a code with adequate nomenclature and reimbursement value in SIGTAP, so that the test is carried out and covered by the public health network, as it is contained in the PCDT of the disease and the existing APAC does not cover the operational costs for its performance; Patients with chronic phase CML should perform a quantitative PCR every 3 months and, after reaching the MMR, should perform the examination every 6 months, as recommended by international guidelines; Patients should be monitored in reference laboratories that are standardized according to the international scale; The laboratories that are within the reference public centers could absorb all the test demand in Brazil, and other centers could be qualified through an ABHH accreditation; Adequate molecular monitoring may allow some patients to stop taking drugs and selffinancing the molecular test for all SUS patients Conclusion: A solution for the molecular test (BCR-ABL1) funding is urgent to ensure the monitoring of CML patients in SUS. The savings that might be generated with patients that stop taking the medication when adequately monitored may finance the test.


Subject(s)
Humans , Middle Aged , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy , Real-Time Polymerase Chain Reaction , Reimbursement Mechanisms , Unified Health System , Brazil , Genes, abl
3.
Rev. bras. med. fam. comunidade ; 16(43): 2856, 20210126. tab
Article in Portuguese | LILACS | ID: biblio-1282025

ABSTRACT

Este artículo analiza el tema de la lista de pacientes como modelo para vincular a la población con los equipos de Atención Primaria de Salud (APS). Objetivo: destacar las características de la lista de pacientes como modelo de pago. Método: ensayo teórico sobre modelos de pago que analiza el piloto de lista de pacientes de la Secretaría Municipal de- Salud (SMS) de Florianópolis. Para fundamentar los principios de la lista de pacientes, su aplicación se presenta en dos contextos diferentes: (a) en el sistema de salud cerrado, como en las Organizaciones de Mantenimiento de la Salud (HMO) en los Estados Unidos; y (b) en el sistema de salud universal, utilizando el sistema de salud británico como modelo. Discusión: el proyecto piloto de lista de pacientes de la SMS de Florianópolis enfrenta dos problemas estructurales: (a) el sistema de salud universal que caracteriza a la APS brasileña; y (b) el modelo de pago de salarios. Estos dos componentes plantean el desafío de establecer un límite real para las listas de pacientes. Sin límite en el número de pacientes, no es posible ajustar la carga de trabajo de los profesionales de la salud. Adicionalmente, una lista de pacientes basada en el uso repetido y el atendimiento de casos de agudeza fuera de la lista tiende a incrementar la carga de trabajo de los profesionales con el tiempo. No obstante, la lista de pacientes propuesta proporciona una mayor visibilidad de la carga de trabajo facilitando tanto la gestión como el seguimiento de la presión asistencial y la redistribución interna de los pacientes entre los equipos de salud de la APS. También permite justificar la ampliación de los equipos de la Estrategia Salud de Familia (ESF) según datos más fiables sobre la realidad de los servicios e implementar programas de mejora de la calidad. Conclusión: la implementación de la modalidad de vinculación flexible en Florianópolis no tiene impactos positivos directos en la carga de trabajo de los equipos de salud, pero quizás sí de manera indirecta a través de la gestión inteligente de su sistema de APS.


This article discusses the theme of patient list as a model for registering the population to the Primary Health Care (PHC) teams. Objective: to highlight the characteristics of patient list as a payment model. Method: theoretical essay on payment models that analyses the pilot of patient list of the Municipal Health Secretariat (MHS) of Florianopolis. To support the principles of the patient list, its application is presented in two different contexts: (a) in closed health systems, as in the Health Maintenance Organizations (HMO) in the United States; and (b) in universal health systems, using the British health system as a model. Discussion: the Florianopolis MHS patient list pilot-project faces two structural problems: (a) the universal health system that characterises Brazilian PHC; and (b) the salary payment model. These two components pose the challenge of establishing a real cap for patient lists. Without a limit on the number of patients, it is not possible to adjust health professionals' workload. Additionally, a list of patients based on repeated use and on the care of out-of-list acute cases tend to increase the workload of professionals over time. Nonetheless, the proposed list of patients provides greater visibility of the workload facilitating both management and monitoring of care pressure and the internal redistribution of patients among the PHC health teams. It also makes it possible to justify the expansion of Family Health Strategy (FHS) teams according to more reliable data on the reality of services and to implement quality improvement programmes. Conclusion: the implementation of the flexible registering modality in Florianopolis does not have direct positive impacts on the workload of health teams, but perhaps it does indirectly through intelligent management of its PHC system.


Este artigo discute o tema da lista de pacientes como modelo de vinculação da população às equipes de Atenção Primária à Saúde (APS). Objetivo: evidenciar as características da lista de pacientes enquanto modelo de pagamento. Método: ensaio teórico sobre modelos de pagamento que analisa o piloto de lista de pacientes da Secretaria Municipal de Saúde (SMS) de Florianópolis-SC. Para fundamentar os princípios da lista de pacientes apresenta-se sua aplicação em dois contextos diferentes: (a) em sistemas fechados de saúde, como nas Health Maintenance Organizations (HMO) nos Estados Unidos; e (b) em sistemas universais de saúde, utilizando o sistema de saúde britânico como modelo. Discussão: o projeto piloto de lista de pacientes da SMS/Florianópolis enfrenta dois problemas estruturais: (a) o sistema de saúde universal que caracteriza a APS brasileira; e (b) o modelo de pagamento salarial. Esses dois componentes impõem o desafio de se estabelecer um teto real para as listas de pacientes. Sem um limite no número de pacientes não é possível adequar a carga de trabalho dos profissionais de saúde. Adicionalmente, uma lista de pacientes construída com base na utilização repetida e no atendimento de casos agudos não fidelizados tende a aumentar a carga de trabalho dos profissionais com o passar do tempo. Entretanto, a proposta da lista de pacientes confere maior visibilidade da carga de trabalho para a gestão, facilitando o monitoramento da pressão assistencial e a redistribuição interna dos usuários entre as equipes de saúde da APS. Permite também justificar a expansão das equipes de ESF de acordo com dados mais fidedignos da realidade dos serviços e implementar programas de melhoria de qualidade. Conclusão: a implantação da modalidade de vinculação flexível em Florianópolis não traz impactos positivos diretos na carga de trabalho das equipes, mas talvez de forma indireta por meio de uma gestão inteligente da rede da APS.


Subject(s)
Reimbursement Mechanisms , Workload , Contracts , Family Practice
4.
Article in Portuguese | LILACS, ECOS | ID: biblio-1353210

ABSTRACT

Objetivos: Comparar os critérios de formação de preços de medicamentos no Brasil e em países selecionados, analisar o mecanismo de formação de preços de medicamentos no Brasil e analisar o mecanismo de formação de preços de medicamentos em países selecionados. Métodos: Foi realizada uma revisão narrativa da literatura por meio do levantamento de informações em bases de dados, em sites das agências nacionais e organismos internacionais e em literatura "cinzenta", a respeito dos sistemas de saúde e mecanismos de formação de preços de medicamentos no Brasil e nos países selecionados (Austrália, Canadá, Espanha, Estados Unidos, França, Grécia, Itália, Nova Zelândia e Portugal). Resultados: A maioria dos países pesquisados utiliza o referenciamento externo e interno de preços, realiza ajustes e correções de preços ao longo do tempo e faz estudos de avaliação econômica. O valor da terapia ou seu benefício para o paciente ou sistema de saúde é um fator importante tanto na determinação do preço como da incorporação no sistema de saúde. Conclusão: Este trabalho permitiu identificar as semelhanças entre as práticas recomendadas e implementadas internacionalmente e as realizadas no Brasil, bem como os problemas relacionados à definição de preços das novas terapias, além das lacunas no modelo regulatório atual


Objectives: To compare the criteria for setting prices of medicines in Brazil and in selected countries, to analyze the mechanism for setting prices of medicines in Brazil and to analyze the mechanism for setting prices of medicines in selected countries. Methods: A narrative review of the literature was carried out by collecting information in databases, on websites of national agencies and international organizations and in "gray" literature, regarding health systems and price formation mechanisms of medicines in Brazil and selected countries (Australia, Canada, Spain, United States, France, Greece, Italy, New Zealand and Portugal). Results: Most of the countries surveyed use external and internal price referencing, make price adjustments and corrections over time and carry out economic evaluation studies. The value of therapy or its benefit to the patient or health care system is an important factor in both pricing and incorporation into the health care system. Conclusion: This work allowed identify the similarities between the practices recommended and implemented internationally and those carried out in Brazil, as well as the problems related to the pricing of new therapies, in addition to the gaps in the current regulatory model


Subject(s)
Reimbursement Mechanisms , Drug Price , Health Systems , Drug Costs , Costs and Cost Analysis
5.
Medwave ; 20(9): e8041, 30-10-2020.
Article in Spanish | LILACS | ID: biblio-1140190

ABSTRACT

INTRODUCCIÓN: Los sistemas de salud se desarrollan en ámbitos complejos y con fallas constantes (incertidumbre, asimetría de información, problema de relación de agencia e inducción de demanda). Estas fallas determinan las relaciones e incentivos entre los actores y se basan en la imperfección del sector. Frente a ello, los mecanismos de pago regulan aspectos del comportamiento e incentivos del sistema, participando como instrumentos de compra de atenciones de salud a prestadores, mediados por los seguros de salud en representación de los usuarios. OBJETIVO: Caracterizar los elementos básicos de las tipologías más frecuentes de los mecanismos de pago con el propósito de para apoyar la labor de los prestadores en su relación con pagadores. MÉTODOS: Se condujo una revisión dirigida de la evidencia en PubMed, Google, Google Scholar y selección estratégica en bola de nieve. Los mecanismos de pago están conformados por tres variables microeconómicas clásicas fijas o variables: precio, cantidad y gasto; y dimensiones temporales utilizadas para analizar sus atributos y efectos. De la combinación de estas variables surgen distintos mecanismos. RESULTADOS: Entre los más utilizados se describen: pago por servicio, presupuesto global, Bundled Payments, grupos relacionados de diagnóstico, per cápita, pago por desempeño y acuerdos de riesgo compartido. Dentro de sus variables ha cobrado importancia una cuarta, el riesgo financiero. CONCLUSIONES: Los mecanismos de pago resultan esenciales para concatenar esfuerzos sanitarios con la práctica clínica. Permiten regular relaciones entre seguros, prestadores y usuarios. Dependiendo de la arquitectura del mecanismo, estas pueden tornarse beneficiosas o entorpecer el cumplimiento de los objetivos del sistema sanitario.


INTRODUCTION: Healthcare systems are developed in imperfect scenarios, in which there are constant failures (uncertainty, information asymmetry, agency relationship problem, and supply-induced demand). These failures, based on the imperfection of the sector, determine the relationships and incentives between the actors. It is within this context that payment mechanisms regulate aspects of the system behavior and incentives, acting as instruments for the purchasing of health care from providers, mediated by health insurance on behalf of users. OBJECTIVE: To characterize the basic elements of most frequent payment mechanisms to help providers in their relationship with payers. METHODS: A review of the evidence was conducted in PubMed, Google, Google Scholar, and strategic snowball selection. Payment mechanisms consist of three classical microeconomics variables, fixed or variable: price, quantity, and expense. Time dimensions are used to analyze their attributes and effects. Different mechanisms emerge from the combination of these variables. RESULTS: Among the most used are: Fee-For-Service, Global Budget, Bundled Payments, Diagnosis-Related Groups, Per-capita, Performance Pay, and Risk-Sharing Agreements. A fourth has also gained importance: Financial Risk. CONCLUSIONS: Payment mechanisms are essential to link health efforts with clinical practice. They make it possible to regulate relationships between insurers, providers, and users, which, depending on the architecture of the mechanism, can become beneficial or hinder the fulfillment of the objectives of the health system.


Subject(s)
Humans , Fee-for-Service Plans , Delivery of Health Care , Diagnosis-Related Groups
6.
Medwave ; 20(4): e7910, 2020.
Article in English, Spanish | LILACS | ID: biblio-1103968

ABSTRACT

INTRODUCCIÓN Los mecanismos de pago corresponden a la operacionalización de la función de compra en salud, incentivando comportamientos en los proveedores de servicios sanitarios. Resulta pertinente preguntarse cómo afectan la vía de resolución del parto, considerando el aumento generalizado en índices de cesárea a nivel global. OBJETIVO: Describir los mecanismos de pago existentes para la atención del parto en países miembros y no miembros de la Organización para la Cooperación y el Desarrollo Económico. MÉTODOS: Revisión sistemática exploratoria (scoping review). Se adoptaron los cinco pasos metodológicos del Joanna Briggs Institute. La búsqueda se realizó por las investigadoras de forma independiente, logrando la confiabilidad interevaluador (κ 0,96) en bases de datos electrónicas, otras fuentes de información, sitios web gubernamentales y no gubernamentales. Se tamizó en tres niveles, considerando literatura no mayor a 10 años de antigüedad, idioma inglés y español. Se analizaron los resultados considerando el funcionamiento del mecanismo de pago y sus efectos en prestado-res, seguros y beneficiarias. RESULTADOS: Se obtuvo evidencia de 34 países (50% pertenecientes a la Organización para la Cooperación y el Desarrollo Económico). El 64% con uso de más de un mecanismo de pago para el parto. Entre los mecanismos más utilizados están: grupos relacionados de diagnósticos (47,6%), pago por resultados (23,3%), pago por servicios (16,6%) y pago fijo prospectivo (13,3%). CONCLUSIÓN: Los países recurren a la arquitectura de los mecanismos de pago para mejorar indicadores en salud materno-perinatales. Es necesario explorar cuál sería la mejor combinación de mecanismos que mejora la provisión de atenciones de salud y bienestar de la población, en el campo de la salud sexual y reproductiva.


INTRODUCTION: Payment mechanisms serve to put into operation the function of purchasing in health. Payment mechanisms impact the decisions that healthcare providers make. Given this, we are interested in knowing how they affect the generalized increase of C-section rates globally. OBJECTIVE: The objective of this review is to describe existing payment mechanisms for childbirth in countries members of the Organization for Economic Co-operation and Development (OECD) and non-members. METHODS: We conducted a scoping review following the five methodological steps of the Joanna Briggs Institute. The search was conducted by researchers independently, achieving inter-reliability among raters (kappa index, 0.96). We searched electronic databases, grey literature, and governmental and non-governmental websites. We screened on three levels and included documents published in the last ten years, in English and Spanish. RESULTS: were analyzed considering the function of the reimbursement mechanism and its effects on providers, payers, and beneficiaries. Results Evidence from 34 countries was obtained (50% OECD members). Sixty-four percent of countries report the use of more than one payment mechanism for childbirth. Diagnosis-Related Groups (47.6%), Pay-for-performance (23.3%), Fee-for-service (16.6%) and Fixed-prospective systems (13.3%) are among the most frequently used mechanisms. CONCLUSION: Countries use payment mechanism architecture to improve maternal-perinatal health indicators. Therefore, it is necessary to explore the best combination of mechanisms that improve the provision of health care and welfare of the population in the field of sexual and reproductive health.


Subject(s)
Humans , Female , Pregnancy , Cesarean Section/economics , Delivery, Obstetric/economics , Delivery of Health Care/economics , Reimbursement, Incentive/economics , Cesarean Section/statistics & numerical data , Fee-for-Service Plans/economics , Organisation for Economic Co-Operation and Development
7.
Cad. Ibero Am. Direito Sanit. (Impr.) ; 8(3): 186-205, jul.-set. 2019.
Article in Portuguese | LILACS, CONASS, ColecionaSUS | ID: biblio-1023220

ABSTRACT

Objetivo: fazer uma análise crítica sobre a tese da responsabilidade solidária pelo fornecimento de medicamentos, fixada pelo Supremo Tribunal Federal com repercussão geral, no Recurso Extraordinário nº 855.178/SE, ao interpretar a competência administrativa comum da União, Estados e Municípios prevista na Constituição Federal relativamente à saúde, de maneira a chamar atenção para a necessidade de se regulamentar os mecanismos de ressarcimento intergovernamental, com vistas a restabelecer o equilíbrio no pacto federativo. Metodologia: pesquisa teórica e documental sobre o ressarcimento interfederativo de ações e prestações de saúde, tendo como norte o caso que ensejou na fixação da tese. A revisão documental foi o procedimento técnico adotado para fazer a observação indireta do objeto pesquisado, por meio de documentos oficiais, adotando-se como fonte secundária a proposição de Súmula Vinculante nº 4 e o Projeto de Lei nº 4.869/2016, disponíveis em sítios oficiais do governo brasileiro. Resultados: a sistemática fixada pelo SupremoTribunal Federal privilegia o acesso à justiça, de maneira a tornar mais célere a concessão judicial de medicamentos e, em razão disso, tende a fomentar a judicialização da saúde. Conclusões: vislumbra-se o descumprimento da segunda parte da tese, referente ao ressarcimento interferativo, haja vista a complexidade e fragilidade da sistemática atual de reembolso intergovernamental. (AU).


Objective: to criticaly analyze the joint liability of federal, state and municipal governments regarding medication supply, stated by Brazil's Supreme Court with general repercussion on the RE 855.178/SE, when construing on the commom competence established in the Federal Constitution, in order to draw attention to the need to regulate the reimbursement mechanisms of federation entities so the balance of the federative pact is restored. Methodology: theoretical and documentary research on the federation entities reimbursement mechanisms regarding the right to health, focusing mainly on the case that has led to the judicial decision in question. The documentary revision was the technical procedure adopted in order to proceed to the indirect observation through official documents, using as sources of secondary data the proposition of Súmula Vinculante nº 4 e the bill nº 4.869/2016, available on Brazilian government's official websites. Results: the reimbursement mechanism stated by Brazil's Supreme Court privileges the access to justice by making judicial granting of medication a faster mechanism and, because of that, it tends to increase judicialization of the right to health. Conclusions: it is foreseen the failing to comply with the second part of the established method, regarding the reimbursement of federation entities, due to the intricacy and weakness of the current reimbursement system. (AU).


Objetivo: hacer un análisis crítico de la tesis de responsabilidad solidaria por el fornecimiento de medicamentos, establecida con repercusión general por el STF, en el RE 855.178/SE, cuando interpreta la competencia administrativa común de la Unión, de los estados y de los municipios, prevista por la Constitución Federal en relación a la salud, de manera a llamar la atención para la necesidad de reglamentarse los mecanismos intergubernamentales de resarcimiento, restableciéndose el equilibrio en el pacto federativo. Metodología: investigación teórica y documental acerca del resarcimiento interfederativo en las acciones y prestaciones de salud, teniendo como Norte el caso que ha conducido a la fijación de la tesis. La revisión documental fue el procedimiento técnico adoptado para proceder a la observación indirecta del objeto investigado, por intermedio de documentos oficiales, habiéndose adoptado como fuente secundaria la propuesta de Súmula Vinculante nº 4 y el Proyecto de Ley 4.869/2016, disponibles en los sitios internet oficiales del gobierno brasileño. Resultados: la sistemática fijada por el STF privilegia el acceso a la justicia, tornando más célere la concesión judicial de medicamentos y, por ello, puede fomentar la judicialización de la salud. Conclusiones: se entiende que no se va a sostener la segunda parte de la tesis, referente al resarcimiento interfederativo, debido a la complejidad y a la fragilidad del actual sistema de resarcimiento intergubernamental. (AU).


Subject(s)
Reimbursement Mechanisms , Liability, Legal , Judicial Decisions , Federalism , Health's Judicialization
8.
Braspen J ; 33(2): 206-210, 2018. tab, fig
Article in Portuguese | LILACS | ID: biblio-910163

ABSTRACT

Introdução: A desnutrição representa um alto custo hospitalar, decorrente de gastos com medi� camentos, exames e terapia nutricional em maior tempo de internação. Nos hospitais públicos, o Sistema Único de Saúde (SUS) repassa um valor diário por paciente para subsidiar os custos com nutrição enteral (NE). O objetivo do trabalho foi descrever os custos diretos com NE em pacientes hospitalizados e avaliar o percentual desses custos em relação ao repasse do SUS. Método: Estudo transversal e descritivo desenvolvido no Setor de Terapia Nutricional de um hospital público. Os custos diretos foram quantificados de acordo com consumo e custo diário de fórmulas enterais, frascos e equipos, número de pacientes por dia em uso de nutrição enteral (NE): por sonda e por suplementação nutricional oral (SNO). Os valores obtidos foram utilizados para avaliar o percentual de cobertura do valor padrão repassado pelo SUS. Resultados: No período avaliado, foram quantificadas 2066 solicitações de NE para pacientes (69,4% com NE por sonda e 30,6% com SNO). O custo médio diário por paciente em uso de NE por sonda foi de R$ 23,89 (60,0% referente à fórmula, 30,2% ao equipo, 7,7% ao frasco e 2,1% ao módulo proteico) e em uso de SNO foi de R$ 6,17 (95,7% referente à fórmula, 3,3% do frasco e 1,0% do módulo proteico). Isso representou uma cobertura do valor repassado pelo SUS de, respectivamente, 79,6% e 20,2%. Na NE por sonda, os custos estimados diários com fórmulas foram: semielementares (R$ 22,65), especializadas (R$ 19,58), hipercalórica/hiperproteica (R$ 13,13) e normocalórica/hiperproteica (R$ 10,26). Na SNO, foram de hipercalóricos/hiperproteicos (R$ 6,12), semielementares (R$ 5,80), especializados (R$ 5,43) e normocalóricos/hiperproteicos (R$ 3,51). Conclusões: Observa-se no estudo que o valor repassado pelo SUS com terapia nutricional enteral provavelmente se mostra insuficiente, principalmente para cobrir os custos com NE por sonda.


Subject(s)
Dietary Supplements , Direct Service Costs , Enteral Nutrition , Food, Formulated , Reimbursement Mechanisms
9.
Journal of the Korean Medical Association ; : 927-933, 2014.
Article in Korean | WPRIM | ID: wpr-191048

ABSTRACT

Whether or not insurance covers new health technology has a great effect on the extent of its acceptance and diffusion. Thus many stakeholders vie to participate in determining insurance reimbursement regulations. This paper explains the process by which new health care technology is added to the coverage list in the Republic of Korea,with each checkpoint explained. Our paper also argues that the implication of the listing process of Korean insurance coverage should be modified in the area such as what is the principle of insurance coverage and who will decide the acceptance criteria of health technology, safety, effectiveness, economic feasibility, and relative value.


Subject(s)
Biomedical Technology , Diffusion , Insurance , Insurance Coverage , Reimbursement Mechanisms , Social Control, Formal
SELECTION OF CITATIONS
SEARCH DETAIL